Clinical Trial Update: Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of a radiolabeled monoclonal antibody for relapsed or refractory Non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Lymphoma | Phase 1 | Status: TERMINATED